A Phase I Single-Institution, Open-Label, Dose-Escalating, Clinical and Pharmacokinetic Study of PM 02734 Administered Every 3 Weeks, Intravenously, Over 30 Minutes, to Subjects With Advanced Malignant Solid Tumors.

Trial Profile

A Phase I Single-Institution, Open-Label, Dose-Escalating, Clinical and Pharmacokinetic Study of PM 02734 Administered Every 3 Weeks, Intravenously, Over 30 Minutes, to Subjects With Advanced Malignant Solid Tumors.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Elisidepsin (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors PharmaMar
  • Most Recent Events

    • 13 Jun 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 13 Jun 2011 Planned end date changed from 1 Sep 2010 to 1 May 2011 as reported by ClinicalTrials.gov.
    • 23 Nov 2010 New source identified and integrated (United Kingdom Clinical Research Network).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top